Since PDL-1 has been implicated in tumor tolerance, it may be directed as a therapeutic biomarker using checkpoint inhibitors such as anti-programmed cell death protein 1 or anti-PDL-1 [53]. The gene discussed is CD274; the disease is neoplasm.